Subcutaneous immunotherapy (SCIT) is effective for allergic rhinitis and conjunctivitis, asthma, and insect venom hypersensitivity. The risk of severe allergic reactions induced by SCIT remains low, and mild systemic reactions have recently shown a tendency to decline. However, near-fatal and fatal anaphylactic reactions may occur. Clinicians administering allergen-specific immunotherapy should receive specialized training and be aware of risk factors and preventive measures to avoid severe allergic reactions induced by SCIT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.iac.2019.09.001 | DOI Listing |
Publication Analysis
Top Keywords
subcutaneous immunotherapy
8
risk factors
8
severe allergic
8
allergic reactions
8
reactions induced
8
induced scit
8
immunotherapy safety
4
safety incidence
4
incidence surveys
4
surveys risk
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!